MELBOURNE, Australia--(BUSINESS WIRE)--Anadis Limited (ASX:ANX), a biotechnology company focused on the use of polyclonal antibodies for human health, has announced a successful conclusion to a private placement, raising US$600,000 from U.S. and Australian investors. This follows an equity credit line of $5 million which the company signed this summer.
